"Global Central Nervous System Disorders Therapeutics Market Overview:
Global Central Nervous System Disorders Therapeutics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Central Nervous System Disorders Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Central Nervous System Disorders Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Central Nervous System Disorders Therapeutics Market:
The Central Nervous System Disorders Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Central Nervous System Disorders Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Central Nervous System Disorders Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Central Nervous System Disorders Therapeutics market has been segmented into:
Neurodegenerative Disorders {Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
and Others}
Infectious Diseases
Psychotic Disorders
Anxiety Disorders
Trauma
Mood Disorders
and Others
By Application, Central Nervous System Disorders Therapeutics market has been segmented into:
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Central Nervous System Disorders Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Central Nervous System Disorders Therapeutics market.
Top Key Players Covered in Central Nervous System Disorders Therapeutics market are:
Biogen Inc.
Pfizer Inc.
Eli Lilly and Company
Merck & Co.
Inc.
Novartis AG
AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Glaxosmithkline plc.
Otsuka Pharmaceutical Co. Ltd
Dr. Reddy's Laboratories Ltd.
Cipla Inc.
Lupin Ltd
Glenmark Pharmaceuticals
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Central Nervous System Disorders Therapeutics Market by Type
4.1 Central Nervous System Disorders Therapeutics Market Snapshot and Growth Engine
4.2 Central Nervous System Disorders Therapeutics Market Overview
4.3 Neurodegenerative Disorders {Alzheimer’s Disease
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Neurodegenerative Disorders {Alzheimer’s Disease: Geographic Segmentation Analysis
4.4 Parkinson’s Disease
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Parkinson’s Disease: Geographic Segmentation Analysis
4.5 Multiple Sclerosis
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Multiple Sclerosis: Geographic Segmentation Analysis
4.6 and Others}
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 and Others}: Geographic Segmentation Analysis
4.7 Infectious Diseases
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Infectious Diseases: Geographic Segmentation Analysis
4.8 Psychotic Disorders
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Psychotic Disorders: Geographic Segmentation Analysis
4.9 Anxiety Disorders
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Anxiety Disorders: Geographic Segmentation Analysis
4.10 Trauma
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 Trauma: Geographic Segmentation Analysis
4.11 Mood Disorders
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 Mood Disorders: Geographic Segmentation Analysis
4.12 and Others
4.12.1 Introduction and Market Overview
4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.12.3 Key Market Trends, Growth Factors and Opportunities
4.12.4 and Others: Geographic Segmentation Analysis
Chapter 5: Central Nervous System Disorders Therapeutics Market by Application
5.1 Central Nervous System Disorders Therapeutics Market Snapshot and Growth Engine
5.2 Central Nervous System Disorders Therapeutics Market Overview
5.3 Analgesics
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Analgesics: Geographic Segmentation Analysis
5.4 Anti-cholinergic Agents
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Anti-cholinergic Agents: Geographic Segmentation Analysis
5.5 Anticonvulsants
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Anticonvulsants: Geographic Segmentation Analysis
5.6 Sedatives and Hypnotics
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Sedatives and Hypnotics: Geographic Segmentation Analysis
5.7 Antidepressants
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Antidepressants: Geographic Segmentation Analysis
5.8 Antipsychotics
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Antipsychotics: Geographic Segmentation Analysis
5.9 and Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Central Nervous System Disorders Therapeutics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BIOGEN INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 PFIZER INC.
6.4 ELI LILLY AND COMPANY
6.5 MERCK & CO.
6.6 INC.
6.7 NOVARTIS AG
6.8 ASTRAZENECA PLC.
6.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
6.11 ABBVIE INC.
6.12 GLAXOSMITHKLINE PLC.
6.13 OTSUKA PHARMACEUTICAL CO.
6.14 LTD.
6.15 DR. REDDY'S LABORATORIES LTD.
6.16 CIPLA INC.
6.17 LUPIN LTD
6.18 AND GLENMARK PHARMACEUTICALS
Chapter 7: Global Central Nervous System Disorders Therapeutics Market By Region
7.1 Overview
7.2. North America Central Nervous System Disorders Therapeutics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.2.4.2 Parkinson’s Disease
7.2.4.3 Multiple Sclerosis
7.2.4.4 and Others}
7.2.4.5 Infectious Diseases
7.2.4.6 Psychotic Disorders
7.2.4.7 Anxiety Disorders
7.2.4.8 Trauma
7.2.4.9 Mood Disorders
7.2.4.10 and Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Analgesics
7.2.5.2 Anti-cholinergic Agents
7.2.5.3 Anticonvulsants
7.2.5.4 Sedatives and Hypnotics
7.2.5.5 Antidepressants
7.2.5.6 Antipsychotics
7.2.5.7 and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Central Nervous System Disorders Therapeutics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.3.4.2 Parkinson’s Disease
7.3.4.3 Multiple Sclerosis
7.3.4.4 and Others}
7.3.4.5 Infectious Diseases
7.3.4.6 Psychotic Disorders
7.3.4.7 Anxiety Disorders
7.3.4.8 Trauma
7.3.4.9 Mood Disorders
7.3.4.10 and Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Analgesics
7.3.5.2 Anti-cholinergic Agents
7.3.5.3 Anticonvulsants
7.3.5.4 Sedatives and Hypnotics
7.3.5.5 Antidepressants
7.3.5.6 Antipsychotics
7.3.5.7 and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Central Nervous System Disorders Therapeutics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.4.4.2 Parkinson’s Disease
7.4.4.3 Multiple Sclerosis
7.4.4.4 and Others}
7.4.4.5 Infectious Diseases
7.4.4.6 Psychotic Disorders
7.4.4.7 Anxiety Disorders
7.4.4.8 Trauma
7.4.4.9 Mood Disorders
7.4.4.10 and Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Analgesics
7.4.5.2 Anti-cholinergic Agents
7.4.5.3 Anticonvulsants
7.4.5.4 Sedatives and Hypnotics
7.4.5.5 Antidepressants
7.4.5.6 Antipsychotics
7.4.5.7 and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Central Nervous System Disorders Therapeutics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.5.4.2 Parkinson’s Disease
7.5.4.3 Multiple Sclerosis
7.5.4.4 and Others}
7.5.4.5 Infectious Diseases
7.5.4.6 Psychotic Disorders
7.5.4.7 Anxiety Disorders
7.5.4.8 Trauma
7.5.4.9 Mood Disorders
7.5.4.10 and Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Analgesics
7.5.5.2 Anti-cholinergic Agents
7.5.5.3 Anticonvulsants
7.5.5.4 Sedatives and Hypnotics
7.5.5.5 Antidepressants
7.5.5.6 Antipsychotics
7.5.5.7 and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Central Nervous System Disorders Therapeutics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.6.4.2 Parkinson’s Disease
7.6.4.3 Multiple Sclerosis
7.6.4.4 and Others}
7.6.4.5 Infectious Diseases
7.6.4.6 Psychotic Disorders
7.6.4.7 Anxiety Disorders
7.6.4.8 Trauma
7.6.4.9 Mood Disorders
7.6.4.10 and Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Analgesics
7.6.5.2 Anti-cholinergic Agents
7.6.5.3 Anticonvulsants
7.6.5.4 Sedatives and Hypnotics
7.6.5.5 Antidepressants
7.6.5.6 Antipsychotics
7.6.5.7 and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Central Nervous System Disorders Therapeutics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Neurodegenerative Disorders {Alzheimer’s Disease
7.7.4.2 Parkinson’s Disease
7.7.4.3 Multiple Sclerosis
7.7.4.4 and Others}
7.7.4.5 Infectious Diseases
7.7.4.6 Psychotic Disorders
7.7.4.7 Anxiety Disorders
7.7.4.8 Trauma
7.7.4.9 Mood Disorders
7.7.4.10 and Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Analgesics
7.7.5.2 Anti-cholinergic Agents
7.7.5.3 Anticonvulsants
7.7.5.4 Sedatives and Hypnotics
7.7.5.5 Antidepressants
7.7.5.6 Antipsychotics
7.7.5.7 and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Central Nervous System Disorders Therapeutics Scope:
|
Report Data
|
Central Nervous System Disorders Therapeutics Market
|
|
Central Nervous System Disorders Therapeutics Market Size in 2025
|
USD XX million
|
|
Central Nervous System Disorders Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Central Nervous System Disorders Therapeutics Base Year
|
2024
|
|
Central Nervous System Disorders Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals.
|
|
Key Segments
|
By Type
Neurodegenerative Disorders {Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
and Others}
Infectious Diseases
Psychotic Disorders
Anxiety Disorders
Trauma
Mood Disorders
and Others
By Applications
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
and Others
|
